| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for November 7-10 in New Orleans, Louisiana. These new data supported by Amarin will further reinforce the robust efficacy of VASCEPA®/VAZKEPA® (icosapent ethyl) in cardiovascular risk reduction (CVRR) as well as highlight the pleiotropic mechanism of action of Eicosapentaenoic Acid (EPA).
Data being featured at the AHA Scientific Sessions include new analyses from the REDUCE-IT study evaluating the clinical benefit of Icosapent Ethyl (IPE) on cardiovascular (CV) outcomes with or without baseline use of aspirin. Alongside this data is a series of mechanistic studies that explore the anti-oxidant effects of EPA on lipoprotein(a) [Lp(a)] as well as anti-inflammatory and endothelial-protective properties.
Featured Amarin-supported abstracts to be presented by academic collaborators (italicized below) at AHA Scientific Sessions 2025 include:
Abstract Board Session
Moderated Digital Poster Presentations
Posted In: AMRN